Fridays tirzepatide: November 2026 price and position
As of November 20, 2026, Fridays’s page shows compounded tirzepatide from $99 ("as low as" with a coupon code) but no month-to-month price, so its regular monthly cost could not be confirmed. Ask for the all-in price at your dose before paying.
Released · Last reviewed · how we verify
Fridays tirzepatide prices, read November 20, 2026
| Measure | Amount | Basis |
|---|---|---|
| Month to month, all-in | from $99 | lowest printed: "as low as" with a coupon code; no month-to-month figure |
| Lowest printed rate | $99 | "as low as" with a coupon code |
Limitations and what to check before you enroll
Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound; it is made for an individual patient by a state-licensed pharmacy. Ask Fridays for the all-in price at the maintenance dose, what is charged today and how often, and which pharmacy fills the prescription. A clinician decides whether any GLP-1 is right for you.
Frequently asked
How much does Fridays charge for tirzepatide?
As of November 20, 2026, Fridays’s page shows compounded tirzepatide from $99 ("as low as" with a coupon code) but no month-to-month price, so its regular monthly cost could not be confirmed. Ask for the all-in price at your dose before paying.
Is Fridays’s tirzepatide FDA-approved?
No. Compounded tirzepatide from any telehealth program, Fridays included, is not FDA-approved and is not the same product as Zepbound or Mounjaro. It is made for an individual patient by a state-licensed compounding pharmacy. Brand Zepbound is the FDA-approved version.
Where do these Fridays figures come from?
From Fridays’s own page (first-party read, promotional, November 20, 2026), converted to an all-in month-to-month figure (medication plus any required recurring fee, before tax). The source link and read date are listed below, and the same figures are in the open dataset.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Fridays pricing page (read November 20, 2026)